Vepdegestrant becomes the first FDA-approved heterobifunctional protein degrader (PROTAC) in breast cancer, targeting ER ...
Combination of eribulin with trastuzumab and pertuzumab for HER2 positive advanced or recurrent breast cancer: JBCRGM03. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...
Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study In light of evolving evidence that some patients with node-positive estrogen receptor–positive ...
The presence of the progesterone receptor marks this tumor as hormone-responsive and indicates that hormone therapy should be considered as a component of her adjuvant therapy. In some breast cancer ...
– Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with ...
A preoperative trial shows that activating the progesterone receptor with low-dose megestrol can deepen estrogen blockade and curb tumor proliferation, without added toxicity, pointing to a simpler ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results